Ro Weight Loss vs Hims Weight Loss: GLP-1 Access and Pricing Compared

——————————————————————————–

Ro weight loss and Hims weight loss are two of the largest GLP-1-focused telehealth programs from broadly direct-to-consumer platforms. Both grew explosively during the GLP-1 boom of 2022-2023, both pivoted significantly with the 2024-2025 changes to the FDA semaglutide and tirzepatide shortage lists, and both now operate primarily through branded GLP-1 delivery with only limited compounded options remaining. This ro weight loss vs hims weight loss comparison breaks down 2026 pricing, clinical models, medication access, and where each platform delivers better value. The short version: Hims has historically been more aggressive on promotional pricing, and Ro has a slightly cleaner program structure – but the differences are smaller than the marketing suggests. Whether a GLP-1 is appropriate for you at all, and which medication and dose, is a decision for a licensed clinician; this article is educational and is not medical advice, and we have no affiliation with either company.

Ro vs Hims weight loss – pricing in 2026

Prices below are approximate and change frequently with promotions and plan changes. Treat them as a starting point and verify current figures on each platform before you enroll.

Ro Body weight loss program (approximate, verify current):

• Initial visit: around $99
• Monthly membership: roughly $145/month (separate from medication)
• Compounded GLP-1s when available: historically about $250-450/month – largely wound down as of 2026
• Branded Wegovy/Zepbound: roughly $500-1,000+/month depending on manufacturer cash programs and coverage
• Includes: clinician evaluation, ongoing care, lab work review, prescription management

Hims weight loss program (approximate, verify current):

• Initial visit: around $79
• Monthly cost: roughly $99-199/month for ongoing care, plus medication
• Compounded GLP-1s: previously about $199-299/month, mostly phased out by 2025
• Branded Wegovy/Zepbound: roughly $500-1,000+/month without robust insurance
• Promotional pricing often available at signup (which is why headline numbers move)

The pricing gap between the two programs is small at the visit and membership level. Medication pricing is similar for branded GLP-1s – both platforms pass through manufacturer-set rates and manufacturer cash-pay programs – and was historically similar for compounded options where those were available. Because Hims runs promotions frequently, the “cheaper” platform can flip month to month, so compare the total 12-month cost, not just the intro offer. See our individual Ro review and Hims review for platform-level detail.

What changed with the 2024-2025 FDA shortage list updates

Through 2024, both Ro and Hims aggressively marketed compounded semaglutide in the $199-299 per month range, drawing significant patient volume into their weight-loss programs. Compounding was legally permitted under FDA rules only while the branded drugs were in shortage.

The FDA declared the tirzepatide shortage resolved in late 2024 and removed semaglutide from the shortage list in early 2025, with enforcement grace periods for compounding pharmacies that ran out during 2025. Those decisions forced both platforms to phase out most compounded options. As of 2026, both Ro and Hims primarily prescribe branded Wegovy and Zepbound for new patients, and the FDA has publicly warned that compounded GLP-1s “should only be used in patients whose medical needs cannot be met by an FDA-approved drug.” Any remaining compounded access is narrow and prescriber-directed – not the mass-market, low-cost channel it was in 2024. (Verify current availability, because the regulatory picture around compounding continues to shift.)

This shift fundamentally changes the value proposition of both platforms. The “low-cost compounded GLP-1 access” that drove growth in 2024 is largely gone. Both platforms now compete primarily on branded medication delivery, where pricing is set by manufacturers rather than by the platforms, and on the quality of the surrounding clinical care.

The Hims-Novo Nordisk split and 2026 settlement

One development worth understanding before you choose: in 2025, Hims & Hers and Novo Nordisk publicly ended a short-lived arrangement to offer branded Wegovy through Hims. Novo accused Hims of continuing to sell compounded or “knockoff” semaglutide and of deceptive promotion; Hims disputed the characterization. The two sides later reached a reported settlement in early 2026 (verify current terms, as details evolved). The practical takeaway for patients is simple: both companies now emphasize branded, FDA-approved GLP-1s, compounded access has largely wound down, and you should treat any “official partner” or guaranteed-brand marketing claim as something to confirm directly rather than assume. It does not change the fact that a legitimate prescription for Wegovy or Zepbound filled through either platform is the same FDA-approved product dispensed at a retail pharmacy.

Clinical model – both similar

Both platforms use a similar clinical model: a video-based or asynchronous initial evaluation with a licensed clinician, eligibility screening based on FDA labeling (generally BMI 27+ with a weight-related comorbidity, or 30+ without), contraindication assessment including personal or family history of medullary thyroid carcinoma and MEN 2 per FDA guidance, and ongoing monthly check-ins for prescription management. Eligibility and dosing are set by the prescriber, not by you or by the platform’s marketing.

The clinical depth at both platforms is reasonable but not exceptional. Calibrate offers more intensive structured coaching, and Found offers a more comprehensive clinical assessment with a broader medication formulary. Ro and Hims occupy a middle position – competent medical management with minimal wraparound coaching. If you have significant medical complexity, coordinate GLP-1 therapy with your own primary care clinician regardless of which platform you use.

Medication delivery and pharmacy partnerships

Both platforms operate or partner with pharmacies that ship GLP-1 medications directly to patients. Ro Pharmacy is operated by Ro itself; Hims partners with affiliated pharmacies for distribution.

For branded Wegovy and Zepbound, pricing is set by the manufacturers (Novo Nordisk and Eli Lilly, respectively) and by their cash-pay programs such as NovoCare and LillyDirect self-pay pricing. Both platforms can coordinate with manufacturer savings programs and discount cards to reduce out-of-pocket cost for eligible patients, and both can coordinate with a patient’s insurance for branded medications when coverage applies. Because manufacturer cash programs and their eligibility rules change often, confirm the current self-pay price for your specific drug and dose before committing.

Insurance coordination

Neither platform bills insurance for the program fee or the visit. Both can coordinate prescriptions with patient insurance for branded GLP-1 medications, which is where most of the medication cost lives. The insurance-navigation experience is broadly similar at both platforms – neither does all the work for the patient, but both provide guidance on prior authorization and coverage.

For patients with strong GLP-1 insurance coverage, both platforms produce similar total costs, since medication insurance handling is the primary cost factor. For patients without coverage, both platforms have similar limitations – branded GLP-1s at retail can clear $1,000+/month before manufacturer cash programs, which is why the self-pay price you are quoted matters more than the platform you pick.

Customer experience and complaints

Both platforms have documented customer-service complaints around auto-renewal billing, cancellation difficulty, and shipping delays for compounded medications during the 2024-2025 transition. The complaint volume is broadly similar in absolute terms.

Hims has historically been a more aggressive marketer with stronger promotional pricing, which produces more first-time signups and proportionally more billing-related complaints. Ro’s experience tends to be slightly more professional in tone and structure but produces similar complaint patterns at scale. Practical advice for either: set calendar reminders before quarterly shipments, read the cancellation terms before you enroll, and verify in writing that a cancellation has actually been processed when you end a subscription.

Specific use cases – when each platform wins

Choose Ro if: You prefer a slightly cleaner program structure with the roughly $145 monthly membership clearly separated from medication costs. You are already using Ro for other health needs (hair loss, ED) and want to consolidate.

Choose Hims if: Hims is running aggressive promotional pricing at the time of signup that makes it cheaper than Ro. You are already using Hims for other needs (hair loss, ED, mental health) and want consolidation. You are a woman seeking weight loss – the parallel Hers brand uses the same infrastructure.

Choose neither if: You want intensive structured coaching beyond what either platform offers. Calibrate and Found provide more clinical depth and coaching support, and our telehealth guide covers how to compare programs generally.

How both compare to Calibrate, Found, and Noom Med

Compared to Calibrate, both Ro and Hims are cheaper at the program level but offer minimal coaching versus Calibrate’s more intensive sessions. Compared to Found, both Ro and Hims have narrower, GLP-1-focused medication formularies versus Found’s broader options. Compared to Noom Med, both Ro and Hims have lighter behavioral content but more streamlined clinical pathways. See Wegovy through Hims vs Ro for the branded-medication-focused comparison.

Frequently Asked Questions

Which is cheaper, Ro or Hims weight loss?

Pricing is comparable and moves with promotions. Hims has historically run more aggressive promotional pricing on the visit fee (around $79 vs $99). Ro’s monthly membership is about $145; Hims’s monthly cost is roughly $99-199 depending on plan. Total cost depends primarily on medication choice, so compare the full quoted price for your specific drug – and verify current figures, since both change often.

Do both prescribe Wegovy?

Yes. Both Ro and Hims prescribe FDA-approved GLP-1 medications including Wegovy and Zepbound for eligible patients, subject to a prescriber’s judgment. Compounded options are limited as of 2026 following the FDA shortage-list updates.

Does either accept insurance?

Neither bills insurance for the visit or program fee. Both can coordinate prescriptions for branded GLP-1 medications, where insurance can apply to the medication itself.

Which has better coaching?

Neither offers intensive coaching. Both provide ongoing clinician check-ins. For substantial coaching support, Calibrate is the stronger choice.

Are GLP-1 prescriptions through Ro or Hims legitimate?

A legitimate prescription for a branded, FDA-approved GLP-1 filled through either platform is the same product dispensed at a retail pharmacy, prescribed by a licensed clinician and shipped from a licensed pharmacy. Be more cautious with any compounded product: the FDA has documented dosing errors, storage problems, and fraudulent products in the compounded GLP-1 market, so confirm what you are actually being prescribed.

The bottom line on Ro weight loss vs Hims weight loss

Ro and Hims weight-loss programs are more similar than different in 2026. Both deliver branded GLP-1 medications with reasonable clinical infrastructure, similar pricing, and comparable customer experiences. Hims has historically run more aggressive promotional pricing; Ro has a slightly cleaner program structure. The 2024-2025 FDA shortage-list updates fundamentally changed both platforms by phasing out most compounded options, and the Hims-Novo dispute underscored that both now lead with branded, FDA-approved GLP-1s. For patients seeking medical weight loss with minimal coaching, either can work. For patients wanting more clinical depth or behavioral support, Calibrate or Found are stronger alternatives. Whichever you consider, confirm current pricing and let a licensed clinician decide whether a GLP-1 is appropriate for you.

Sources

• FDA – “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” (fda.gov)
• FDA – “Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss” (fda.gov)
• FDA Drug Shortages database – semaglutide and tirzepatide status (accessdata.fda.gov)
• Ro (ro.co) and Hims & Hers (hims.com / forhers.com) – program and pricing pages (verify current)